文献速递甲状腺疾病

儿童分化型甲状腺癌疾病持续存在的临床与病理相关因素

Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2025-07-30

这项多中心回顾性队列研究纳入538例≤18岁分化型甲状腺癌患者,中位随访85个月后23.0%存在疾病持续(生化性12.6%、结构性10.4%)。多因素分析显示,甲状腺外侵犯和首次放射性碘治疗后全身扫描淋巴结摄取与疾病持续存在显著相关。

要点

  • 儿童分化型甲状腺癌中,甲状腺外侵犯(OR 2.81)与疾病持续存在独立相关。
  • 首次放射性碘治疗后全身扫描淋巴结摄取与疾病持续存在相关(OR 3.31)。
  • T4肿瘤(OR 4.3)和全身扫描淋巴结摄取(OR 3.39)与结构性不完全反应相关。

核心结论

  • T4肿瘤、全身扫描淋巴结摄取和甲状腺外侵犯是与儿童分化型甲状腺癌疾病持续存在相关的独立因素。
  • 这些发现强调对儿童分化型甲状腺癌进行仔细风险分层的重要性,以实现更个体化的治疗。

研究设计与样本

  • 多中心回顾性队列研究,纳入2000年1月起诊断的≤18岁分化型甲状腺癌患者。
  • 共纳入538例患者,其中女性401/538例(74.5%),中位年龄15岁(四分位距13-17岁)。

主要发现

  • 乳头状甲状腺癌为最常见组织类型,277/530例(52.3%)诊断时存在淋巴结转移。
  • 血管侵犯见于133/326例(40.8%),大体甲状腺外侵犯见于91/533例(17.1%),T4肿瘤占整个队列的5%。
  • 493/533例(92.5%)接受放射性碘治疗,其中138/493例(28%)接受超过一个疗程。
  • 中位随访85个月(四分位距42-126个月)后,414/538例(77%)无疾病证据,124/538例(23.0%)疾病持续:生化性不完全反应68/538例(12.6%),结构性不完全反应56/538例(10.4%)。
  • 多因素分析中,与疾病持续(生化性或结构性不完全反应)显著相关的因素为大体甲状腺外侵犯(OR 2.81,CI 1.49-5.32,p=0.0015)和首次放射性碘治疗后全身扫描淋巴结摄取(OR 3.31,CI 1.77-6.19,p=0.0002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Differentiated thyroid carcinoma (DTC) in pediatric patients has specific clinical, pathological, and molecular characteristics, making its management different from that of adults. Our study aimed to evaluate the outcome and factors associated with persistent disease in a large cohort of pediatric patients. Methods: We performed a multicenter retrospective cohort study, including patients aged ≤18 years, diagnosed with a DTC, since January 2000. Both biochemical (BIR) and structural (SIR) incomplete responses were evaluated. Results: We included 538 patients, 401/538 (74.5%) females, with a median age of 15 years (interquartile range [IQR] 13-17 years). Papillary thyroid cancer was the most prevalent histotype and 277/530 (52.3%) had lymph node metastases at diagnosis. Vascular invasion and gross extrathyroidal extension (ETE) were reported in 133/326 (40.8%) and 91/533 (17.1%) of patients, respectively. T4 tumors represented 5% of the entire cohort. Radioactive iodine treatment (RAIT) was administered to 493/533 (92.5%) patients, and among them 138/493 (28%) received more than one RAIT cycle. After a median follow-up of 85 months (IQR 42-126 months), 414/538 patients (77%) had no evidence of disease and 124/538 patients (23.0%) a disease persistence: BIR in 68/538 patients (12.6%) and SIR in 56/538 patients (10.4%). In a multivariable analysis, the features significantly associated with persistent disease (BIR or SIR) were gross ETE (odds ratio [OR] 2.81, confidence interval [CI] 1.49-5.32, p = 0.0015) and lymph node uptake at whole-body scan (WBS) after the first RAIT (OR 3.31, CI 1.77-6.19, p = 0.0002). Multivariable analysis showed that the features significantly associated with SIR were T4 tumor (OR 4.3, CI 1.38-13.44, p = 0.01) and lymph node uptake at WBS after the first RAIT (OR 3.39, CI 1.5-7.67, p = 0.003). Conclusions: Our study of a very large series of pediatric DTC with long follow-up provides valuable insights into the clinical and pathological features associated with disease persistence. We identified T4 tumor, lymph node uptake on WBS, and gross ETE as independent factors associated with persistent disease. These findings emphasize the importance of careful risk stratification in pediatric DTC, allowing for more individualized treatment approaches.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. De Leo S, Bottici V, Pellegriti G, et al. Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma. Thyroid. 2025. PMID: 40737224. doi:10.1177/10507256251363978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。